FDA issues safety alert over SGLT2-inhibitors

There have been 12 cases of life-threatening necrotising fasciitis in patients with type 2 diabetes

The TGA is looking into a safety issue concerning SGLT-2 inhibitors after the US Food and Drug Administration (FDA) warned a rare genital gangrene has been reported in patients with type 2 diabetes taking the medications.